Humacyte (NASDAQ:HUMA) Sees Strong Trading Volume

Humacyte, Inc. (NASDAQ:HUMA) saw an uptick in trading volume on Tuesday . 638,996 shares changed hands during trading, a decline of 64% from the previous session’s volume of 1,775,598 shares.The stock last traded at $5.32 and had previously closed at $5.37.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Piper Sandler restated a “neutral” rating and issued a $4.00 price objective on shares of Humacyte in a report on Tuesday, March 26th. Cantor Fitzgerald restated an “overweight” rating and issued a $7.00 price objective on shares of Humacyte in a report on Tuesday. Finally, Benchmark restated a “buy” rating and issued a $15.00 price objective on shares of Humacyte in a report on Tuesday.

Humacyte Stock Up 11.0 %

The company has a market cap of $675.18 million, a PE ratio of -5.67 and a beta of 1.52. The business has a fifty day simple moving average of $5.98 and a two-hundred day simple moving average of $4.23. The company has a current ratio of 8.37, a quick ratio of 8.37 and a debt-to-equity ratio of 0.61.

Humacyte (NASDAQ:HUMA) last issued its earnings results on Friday, May 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). As a group, equities research analysts predict that Humacyte, Inc. will post -0.95 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Gordon M. Binder bought 50,000 shares of the business’s stock in a transaction on Wednesday, May 15th. The stock was acquired at an average cost of $6.78 per share, with a total value of $339,000.00. Following the purchase, the director now directly owns 160,000 shares of the company’s stock, valued at $1,084,800. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other Humacyte news, Director Gordon M. Binder acquired 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 15th. The stock was purchased at an average cost of $6.78 per share, with a total value of $339,000.00. Following the transaction, the director now owns 160,000 shares of the company’s stock, valued at $1,084,800. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Laura E. Niklason sold 809,786 shares of the firm’s stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $7.91, for a total value of $6,405,407.26. Following the sale, the chief executive officer now directly owns 5,381,354 shares of the company’s stock, valued at $42,566,510.14. The disclosure for this sale can be found here. In the last three months, insiders purchased 54,412 shares of company stock valued at $369,107 and sold 1,628,820 shares valued at $12,464,121. Corporate insiders own 23.10% of the company’s stock.

Institutional Trading of Humacyte

A number of hedge funds and other institutional investors have recently modified their holdings of HUMA. GSA Capital Partners LLP increased its position in shares of Humacyte by 139.5% during the 3rd quarter. GSA Capital Partners LLP now owns 355,918 shares of the company’s stock worth $1,043,000 after purchasing an additional 207,333 shares during the last quarter. Whittier Trust Co. of Nevada Inc. acquired a new position in Humacyte in the 4th quarter valued at about $28,000. SG Americas Securities LLC grew its position in Humacyte by 52.8% in the 4th quarter. SG Americas Securities LLC now owns 16,340 shares of the company’s stock valued at $46,000 after acquiring an additional 5,645 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in Humacyte by 350.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,986 shares of the company’s stock valued at $34,000 after acquiring an additional 9,325 shares in the last quarter. Finally, United Asset Strategies Inc. grew its position in Humacyte by 53.9% in the 4th quarter. United Asset Strategies Inc. now owns 221,308 shares of the company’s stock valued at $629,000 after acquiring an additional 77,500 shares in the last quarter. 44.71% of the stock is owned by institutional investors and hedge funds.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.